Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05162755 · ClinicalTrials.gov registry record · Phase 1
S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers
A Phase 1 study of Solid Tumor, sponsored by Institut de Recherches Internationales Servier.
- Active
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 5
- Study locations
NCT05162755 is a Phase 1 study of Solid Tumor that is active but no longer recruiting, run by Institut de Recherches Internationales Servier. The registered enrollment target is 41 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (81% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT05162755, a Phase 1 study of Solid Tumor, is active but no longer recruiting, sponsored by Institut de Recherches Internationales Servier.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of the study is to investigate the safety, tolerability, and preliminary anti-neoplastic activity of S095029 alone and in combination with Sym021 in patients with advanced solid tumor malignancies followed by an expansion phase of triple combinations. \*The study sponsor has made the decision not to move forward to the expansion part of the study due to strategic considerations, unrelated to any safety issues or concerns. The study will be stopped after completion of dose escalation parts 1a and 1b of the study.
Conditions Studied
Interventions
- DRUG S095029
- DRUG S95029 and Sym021
Study Locations (5)
Texas
- Mary Crowley Cancer Research - Dallas
- The University of Texas MD Anderson Cancer Center - Houston
- The START Center for Cancer Care - San Antonio
Michigan
- START Midwest - Grand Rapids
Other
- Princess Margaret Cancer Centre - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2021-10-15 |
| Est. Completion | 2026-05-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05162755
The ClinicalTrials.gov registry entry for NCT05162755 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (81% lower). The listed sponsor is Institut de Recherches Internationales Servier, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which S095029 is the first listed.
NCT05162755 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Texas, Michigan, Other.
Frequently Asked Questions
What is clinical trial NCT05162755 about?
NCT05162755 is a clinical study titled "S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers". The purpose of the study is to investigate the safety, tolerability, and preliminary anti-neoplastic activity of S095029 alone and in combination with Sym021 in patients with advanced solid tumor malignancies followed by an expansion phase of triple combinations. \*The study sponsor has made the de...
What is the current status of trial NCT05162755?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2021-10-15. Estimated completion is 2026-05-19.
What conditions does trial NCT05162755 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT05162755?
The interventions under investigation include: S095029 (DRUG), S95029 and Sym021 (DRUG).
Who is sponsoring clinical trial NCT05162755?
This trial is sponsored by Institut de Recherches Internationales Servier, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05162755 being conducted?
This trial has 5 study locations across Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.